This intermittent use pattern, while not extensively studied, may provide a practical approach for individuals who cannot afford or tolerate continuous long term treatment
Beyond appetite suppression, GLP-1 medications may support modest improvements in insulin sensitivity and blood glucose control, which can reduce metabolic inflammation
We wanted to see if losing 20% or more of body weight would have a major effect on mortality, cardiovascular morbidity and other forms of morbidity
Statins remain first-line treatment for elevated cholesterol, with GLP-1 therapy providing complementary cardiovascular benefits
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist with a slightly different mechanism
Even losing 5-10% of your body weight can significantly improve blood sugar levels, reduce A1C, and prevent progression to type 2 diabetes
